Keryx Biopharm Inc (KERX) 7.14 $KERX Keryx

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 11:05 PM

Keryx Biopharm Inc (KERX) 7.14 $KERX

Keryx Biopharmaceuticals Has Returned 51.6% Since SmarTrend Recommendation (KERX)
Comtex SmarTrend(R) - Tue Jul 05, 12:16AM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 4 months, Keryx Biopharmaceuticals has returned 51.62% as of today's recent price of $6.80.
KERX: 7.14 (-0.11)

Keryx Biopharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 8.30%
Comtex SmarTrend(R) - Tue Jun 28, 3:35PM CDT
Keryx Biopharmaceuticals (NASDAQ:KERX) traded in a range yesterday that spanned from a low of $5.91 to a high of $6.29. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $6.20 on volume of 718,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
KERX: 7.14 (-0.11)

Uptrend Call Working As Keryx Biopharmaceuticals Stock Rises 28.5% (KERX)
Comtex SmarTrend(R) - Mon Jun 27, 1:01PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 4 months, Keryx Biopharmaceuticals has returned 28.54% as of today's recent price of $5.77.
KERX: 7.14 (-0.11)

Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016. Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015.
VCEL: 2.27 (+0.05), SCYX: 2.16 (-0.05), CFRX: 2.85 (+0.13), MNTA: 11.40 (-0.01), KERX: 7.14 (-0.11)

Keryx Biopharmaceuticals Has Returned 37.7% Since SmarTrend Recommendation (KERX)
Comtex SmarTrend(R) - Fri Jun 17, 12:55PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 4 months, Keryx Biopharmaceuticals has returned 37.73% as of today's recent price of $6.18.
KERX: 7.14 (-0.11)

Shares of KERX Up 34.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 10, 12:31AM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 34.89% as of today's recent price of $6.05.
KERX: 7.14 (-0.11)

Shares of KERX Up 53.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 02, 1:04PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 53.85% as of today's recent price of $6.90.
KERX: 7.14 (-0.11)

Keryx Biopharmaceuticals Up 22.4% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed May 18, 1:20PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 22.41% as of today's recent price of $5.49.
KERX: 7.14 (-0.11)

Keryx (KERX) Q1 Loss in Line, Auryxia Up on Strong Demand (Revised)
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 12:30PM CDT
Keryx Biopharmaceuticals Inc.'s (KERX) first-quarter 2016 loss of 22 cents per share was in line with the Zacks Consensus Estimate.
SHPG: 186.31 (-1.90), ARQL: 1.71 (-0.03), AEGR: 1.62 (-0.05), KERX: 7.14 (-0.11)

Keryx Biopharma reports 1Q loss
Automated Insights - Thu Apr 28, 8:31AM CDT
BOSTON (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Thursday reported a loss of $41 million in its first quarter.
KERX: 7.14 (-0.11)

3 Healthcare Stocks Billionaires Love Right Now
Brian Feroldi, Keith Speights, and Cory Renauer, The Motley Fool - Motley Fool - Thu Apr 28, 8:04AM CDT
Source: BILL BROOKS, FLICKR CREATIVE COMMONS. 13F reports are filed with the Securities and Exchange Commission by billionaire investors each quarter and make it easy for anyone to track their trades and see what they've been buying and selling...
MRK: 59.34 (-0.01), MYL: 44.55 (+0.01), KERX: 7.14 (-0.11)

Keryx (KERX) Reports Wider-Than-Expected Loss in Q1
Ekta Bagri - Zacks Investment Research - Thu Apr 28, 6:46AM CDT
Keryx (KERX) reported a wider-than-expected loss in the first quarter of 2016 but maintained its outlook for 2016.
KERX: 7.14 (-0.11)

Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 6:04AM CDT
-- Company reported $6.8 million in first quarter total revenues, including $5.6 million of Auryxia(TM) (ferric citrate) net U.S. product sales
KERX: 7.14 (-0.11)

Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 4.71 (-0.08), BIIB: 252.54 (+1.24), JNJ: 122.93 (+0.08), BMRN: 88.59 (-2.90), SHPG: 186.31 (-1.90), IMGN: 2.96 (-0.24), BXLT: 46.02 (-0.18), KERX: 7.14 (-0.11), NVS: 82.31 (+0.18)

What's in Store for Keryx (KERX) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 8:50AM CDT
Keryx Biopharmaceuticals, Inc. (KERX) is scheduled to report first-quarter 2016 results on Apr 28.
BMRN: 88.59 (-2.90), GILD: 86.25 (-0.30), SNY: 41.42 (+0.57), KERX: 7.14 (-0.11)

Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2016 Financial Results on Thursday, April 28, 2016
GlobeNewswire - Thu Apr 14, 7:30AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced that it will host a conference call and webcast on Thursday, April 28, 2016 at 8:00 a.m. ET to discuss its first quarter 2016 financial results.
KERX: 7.14 (-0.11)

Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors
GlobeNewswire - Fri Apr 01, 7:30AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced appointment of two industry leaders to Keryx's board of directors, which increases the size of the company's board to 10 members. These appointments are expected to bring deep, relevant industry experience to Keryx at an important time in the company's growth.
VCEL: 2.27 (+0.05), SCYX: 2.16 (-0.05), CFRX: 2.85 (+0.13), ACOR: 25.57 (-0.64), KERX: 7.14 (-0.11)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Data Center Piping Surges With AI Cooling to $4.5B

Liquid Cooling Revolutionizes Data Center Infrastructure Gotta hand it to the tech world, when it decides to shift, it shifts hard and fast. The data center piping market isn't just keeping up—it's sprinting. The move towards liquid-cooled AI setups isn’t just a trend; it’s a defining transformation. With a projected explosion to a $4.5 billion market by 2035, you...

AI Campuses Drive Surge in Power Cable Market

Surge in Data Center Power Cable Demand Walking down the old data center aisle, you'd never imagine so much copper snaking its way into the modern megalith of AI campuses. But here we are, staring at a market projected to leap from USD 1.74 billion in 2025 to a whopping USD 4.72 billion by 2035. That's a compounded annual growth rate (CAGR) of a robust 10.50%, and it’s...

Rocket Companies' Earnings Preview: What's at Stake?

Anticipation Builds Around Rocket's Earnings Call It ain't every day that a company's earnings announcement stirs up interest the way Rocket Companies' (NYSE:RKT) upcoming third-quarter results have. But here we are, just days away from October 29, 2026, when leadership will lay out the cards at 4:30 p.m. ET. This announcement might just be what investors like us need to...

AMTD Digital's Half-Year Results Stir Investor Interest

AMTD Digital Warming Up for a Busy Quarter Some things just catch the wind differently in the market, and when a heavyweight like AMTD Digital starts talking numbers, everybody perks up. They're gearing up to drop their half-year financials, ready to roll out at the stroke of midnight on October 23rd, and investor ears across the globe are pricked for what’s coming down...

Vertice P2P Aims to Transform Procurement Efficiency

Vertice Dives Deeper into the Procurement Game Grab a coffee and let's talk some procurement—one of the least sexy, yet utterly essential parts of any operation. Vertice's latest announcement is anything but mundane. They're spiraling deeper into the procurement universe with their new Procure-to-Pay (P2P) capability, a bold expansion from their Intake-to-Procure (I2P)...

Lunai Bioworks Voluntarily Delists After Equity Snags

Bracing for the Delisting Impact Well, isn't that a familiar tune? Lunai Bioworks Inc., ticking with the symbol NASDAQ:LNAI, is pulling the plug on its Nasdaq listing faster than a kid yanking out a loose tooth. On October 21, 2026, the company's board decided it's cheaper and simpler to step off the dance floor than keep paying for a spot when the music's stopped....

Centrus Energy to Discuss Q3 Earnings on Nov 5 Call

Centrus Energy Prepares for Earnings Call You ever feel that twinge in your gut right before a big disclosure? Well, that's where Centrus Energy’s about to take us as they gear up for their quarterly earnings call. On November 5th, bright and early at 8:30 a.m. Eastern Time, NYSE:LEU will be in the spotlight, laying out its Q3 results for all us nose-to-the-grindstone...

Venture Dock Fosters Global Startup Ecosystems

Venture Dock Connects the Global Startup Dots When it comes down to bridging the gap between promising innovation and commercial success, you'd be hard-pressed to find a better player than Venture Dock. In a world filled with buzzwords and fluff, these guys are socketed deep in the guts of genuine startup development — and they're making waves with their recent...

Beggin' Unveils Festive Treats for Canine Thanksgiving

Dog Treats That Spice Up Thanksgiving Feast Just when you thought Thanksgiving was all about the humans crowding around a table of turkey and stuffing, Beggin' decides to throw the dogs a bone—literally. These guys rolled out their limited-edition holiday treats that’ll probably have your pup sniffin’ the air like it’s the early days of autumn. What's Cookin' In...

PENNVEST Grants $42M for PA Water Upgrades

Big Boost for Pennsylvania's Water Infrastructure The recent announcement about Pennsylvania American Water scoring a $42 million package from PENNVEST feels like a solid win for everyone except complacency. This move is a direct nod to infrastructure sorely needing an upgrade in Lackawanna and Montgomery counties. You'd think these improvements were long overdue with all...